Johnson & Johnson (NYSE: JNJ), a global leader in healthcare, announced significant progress in the treatment of Sjögren’s disease (SjD) with its drug, nipocalimab. In a recent Phase 2 DAHLIAS study, patients treated with nipocalimab exhibited a statistically significant improvement in their ClinESSDAI score compared to placebo at 24 weeks (P=0.002), marking a major advancement […]
Innovent Biologics, Inc. (HKEX: 01801) has announced remarkable results from the CLEAR-1 Phase 3 registrational study of its novel drug, picankibart (R & D code: IBI112), signaling a major breakthrough in psoriasis treatment. The study demonstrated that picankibart, a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, met all primary and key secondary endpoints, showcasing its […]
